Cosmetic Ingredient Review’s independent experts note that CBD use in cosmetic products has increased since FDA first asked them to prioritize its review in 2020.
Cosmetic Ingredient Review’s Expert Panel For Cosmetic Ingredient Safety will prioritize cannabidiol for review in 2024 at the US Food and Drug Administration’s request.
The agency initially asked the panel to add CBD to its list of 2020 priorities, but CBD had no reported...
Create an account to read this article
Already a subscriber?
FDA’s fourth approval in past two months for color derived from natural sources to use in foods is Gardenia Blue Interest Group’s color additive petition for gardenia blue. Lycored launches StellarYellow and C Clear as alternatives for synthetic dyes yellow Nos. 5 and 6 and OrangeOvation C Clear for
Health Subcommittee will discuss reauthorizing OMUFA during a hearing on how to “maintain and improve” the public health workforce and rural health as well as access to OTC medicines.
The Urban Wastewater Treatment Directive “in its current form, is at an end,” insists Pharma Deutschland CEO Jörg Wieczorek. To put the directive to bed once and for all, the association has applied for leave to intervene in the ongoing EU legal battle in its own right.
Based on advice from its advisory committees, the UK's Food Standards Agency is encouraging businesses to meet an acceptable daily intake of 10mg CBD per day and a safe upper limit of 0.07mg THC per day.
FDA’s fourth approval in past two months for color derived from natural sources to use in foods is Gardenia Blue Interest Group’s color additive petition for gardenia blue. Lycored launches StellarYellow and C Clear as alternatives for synthetic dyes yellow Nos. 5 and 6 and OrangeOvation C Clear for
Stada's Serbian subsidiary Hemofarm has enhanced its offering in the dietary supplements category with the acquisition of Fortacell from Goodwill Pharma.
Subcommittee members aren’t on same page about whether FDA staff cuts ordered by the Trump administration will prevent the agency from fulfilling its responsibilities for the OTC drug sector.
